Anebulo Pharmaceuticals, Inc.
ANEB
$1.05
-$0.02-1.87%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.34% | 20.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.91% | -3.03% | |||
| Operating Income | -15.91% | 3.03% | |||
| Income Before Tax | 7.37% | -0.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.37% | -0.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.37% | -0.63% | |||
| EBIT | -15.91% | 3.03% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 7.24% | -0.57% | |||
| Normalized Basic EPS | 7.32% | -0.61% | |||
| EPS Diluted | 7.24% | -0.57% | |||
| Normalized Diluted EPS | 7.32% | -0.61% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||